



Please type a plus sign (+) inside this box

+

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number	09/341,407
Filing Date	October 12, 1999
First Named Inventor	DELOVITCH, Terry L
Group Art Unit	1644
Examiner Name	J. Roark
Attorney Docket Number	087300-000400US

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
JR	1	BOWMAN et al. "Prevention of diabetes in the NOD mouse: implications for therapeutic intervention in human disease," Immunology Today 15:115-120 (1994)	
	2	EKERFELT et al. "Transfer of myelin-specific cells deviated in vitro towards IL-4 production ameliorates ongoing experimental allergic neuritis," Clin. Exp. Immunol 123:112-118 (2001)	
	3	KARANDIKAR et al. "Tissue-Specific Up-Regulation of B7-1 Expression and Function During the Course of Murine Relapsing Experimental Autoimmune Encephalomyelitis," The Journal of Immunology 161:192-199 (1998)	
	4	SAOUDI et al. "TH2 activated cells prevent experimental autoimmune uveoretinitis, a TH1-dependant autoimmune disease," Eur. J. Immunol. 23:3096-3103 (1993)	
	5	WEINTRAUB et al. "Up-Regulation and the Costimulatory Molecules B7-1 and B7-2 on Peripheral Lymphocytes in Autoimmune B6/gld Mice," The Journal of Immunology 159:4117-4126 (1997)	
JR	6	YU et al. "Expression of GAD65 and Islet Cell Antibody (ICA512) Autoantibodies Among Cytoplasmic ICA+ Relatives is Associated with Eligibility for the Diabetes Prevention Trial-Type 1," Diabetes 50:1735-1740 (2001)	

Examiner
Signature

J. Roark

Date

Considered

11/1/01

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

SEP 28 2001

RECEIVED